Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma.

Minisini AM, Pascoletti G, Intersimone D, Poletto E, Driol P, Spizzo R, Scott CA, Puglisi F, Fasola G, Di Loreto C.

Melanoma Res. 2013 Apr;23(2):96-101. doi: 10.1097/CMR.0b013e32835e7734.

PMID:
23411479
2.

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma.

Johansson CC, Egyházi S, Masucci G, Harlin H, Mougiakakos D, Poschke I, Nilsson B, Garberg L, Tuominen R, Linden D, Stolt MF, Hansson J, Kiessling R.

Cancer Immunol Immunother. 2009 Jul;58(7):1085-94. doi: 10.1007/s00262-008-0631-1. Epub 2008 Nov 28.

PMID:
19039588
4.

Expression of thymidine phosphorylase in human cervical cancer.

Hata K, Takebayashi Y, Iida K, Fujiwaki R, Fukumoto M, Miyazaki K.

Anticancer Res. 1999 Jan-Feb;19(1B):709-16.

PMID:
10216481
5.

COX-2 expression in malignant melanoma: a novel prognostic marker?

Becker MR, Siegelin MD, Rompel R, Enk AH, Gaiser T.

Melanoma Res. 2009 Feb;19(1):8-16. doi: 10.1097/CMR.0b013e32831d7f52.

PMID:
19430402
6.

Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.

Massi D, Franchi A, Sardi I, Magnelli L, Paglierani M, Borgognoni L, Maria Reali U, Santucci M.

J Pathol. 2001 Jun;194(2):194-200.

PMID:
11400148
7.
8.

Thick cutaneous malignant melanoma: a reappraisal of prognostic factors.

Massi D, Borgognoni L, Franchi A, Martini L, Reali UM, Santucci M.

Melanoma Res. 2000 Apr;10(2):153-64.

PMID:
10803716
9.

The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer.

Nonomura N, Nakai Y, Nakayama M, Inoue H, Nishimura K, Hatanaka E, Arima R, Kishimoto T, Miki T, Kuroda H, Okuyama A.

Int J Clin Oncol. 2006 Aug;11(4):297-302.

PMID:
16937303
10.

Cyclooxygenase-2 immunohistochemistry in human melanoma: differences between results obtained with different antibodies.

Kuzbicki L, Lange D, Chwirot BW.

Melanoma Res. 2009 Oct;19(5):294-300. doi: 10.1097/CMR.0b013e32832e0bde.

PMID:
19543125
11.

Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression.

Bianchini F, Massi D, Marconi C, Franchi A, Baroni G, Santucci M, Mannini A, Mugnai G, Calorini L.

Prostaglandins Other Lipid Mediat. 2007 Jun;83(4):320-8. Epub 2007 Mar 13.

PMID:
17499752
12.

[Relationships among the expression of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase and the prognosis of breast cancer].

Yu ZG, Zhen JH, Jia HY, Zhang Q, Sun JZ.

Zhonghua Yi Xue Za Zhi. 2006 Jun 13;86(22):1558-63. Chinese.

PMID:
16854285
13.
14.

Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers.

O'Brien TS, Fox SB, Dickinson AJ, Turley H, Westwood M, Moghaddam A, Gatter KC, Bicknell R, Harris AL.

Cancer Res. 1996 Oct 15;56(20):4799-804.

15.

Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression.

Kuźbicki L, Sarnecka A, Chwirot BW.

Melanoma Res. 2006 Feb;16(1):29-36.

PMID:
16432453
16.

Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.

Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C.

Oncology. 2006;70(5):366-77. Epub 2006 Dec 15.

PMID:
17179731
17.

Co-expression of vascular endothelial growth factor and thymidine phosphorylase in endometrial cancer.

Fujiwaki R, Hata K, Iida K, Maede Y, Watanabe Y, Koike M, Miyazaki K.

Acta Obstet Gynecol Scand. 1999 Sep;78(8):728-34.

PMID:
10468067
18.
19.

Prognostic value of galectin-3 in primary cutaneous melanoma.

Buljan M, Šitum M, Tomas D, Milošević M, Krušlin B.

J Eur Acad Dermatol Venereol. 2011 Oct;25(10):1174-81. doi: 10.1111/j.1468-3083.2010.03943.x. Epub 2010 Dec 22.

PMID:
21175876
20.

Supplemental Content

Support Center